Highlights Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 01:30:00 2025-12-11 EST			5-day change	1st Jan Change
4,471.00 ^JPY	-0.27%		+0.38%	+6.94%

12-07	Takeda, Protagonist Report One-Year Rusfertide Gains in PV trial	MT
12-06	Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera	CI

Highlights

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera	12-06	CI
Innovent Biologics Closes Takeda Partnership, Issues New Shares	12-04	MT
Takeda pharmaceutical conducted thorough assessment, found there was no confirmed causal relationship to use of Adzynma & patient death - spokesperson	11-21	RE
Fda investigates death linked to Adzynma treatment for congenital thrombotic thrombocytopenic purpura	11-21	RE
Takeda Pharmaceutical's Adzynma Under US FDA Probe Following Death of Pediatric Patient	11-21	MT
Alkermes shares tumble as sleep disorder drug shows limited advantage over rival	11-12	RE
Takeda Presents New Data Showing Mezagitamab Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy	11-07	CI
US FDA awards six more fast-track vouchers to speed drug reviews	11-06	RE
Takeda Inc. Announces Completion of the 7-Year Pivotal Phase 3 Tides Trial Evaluating Its Dengue Vaccine, Qdenga®?V	11-03	CI
Takeda Pharmaceutical Company Limited Declares Dividend for Second Quarter-End of Fiscal Year Ending March 31, 2026, Payable on December 1, 2025	10-30	CI
Takeda Pharmaceutical Attributable Profit Falls 40% in Fiscal H1	10-30	MT
Takeda Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended September 30, 2025	10-30	CI
Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Decline; Fiscal 2025 Outlook Trimmed	10-30	MT
Takeda Swings to Loss on Impairment Charges, Cuts Guidance -- Update	10-30	DJ
Takeda Pharmaceutical Company Limited Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026	10-30	CI
Takeda Posts Quarterly Net Loss, Cuts Guidance	10-30	DJ
Takeda Inc. Announces the Recently FDA- Approved Hyhub and Hyhub Duo Devices Now Available in the U.S. to Simplify Hyqvia® Infusion Preparation	10-27	CI
Takeda Forms $1.2 Billion Strategic Partnership with Innovent Biologics	10-22	MT
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market	10-21	CI
Innovent Biologics Sells License to Two Cancer Drugs to Takeda; Shares Up 3%	10-21	MT
Keros Therapeutics to Buy Back Shares From Adar1 Capital, Pontifax for $181 Million	10-15	MT
Takeda Signs Multiyear Research Collaboration With Nabla Bio	10-14	MT
Takeda Pharmaceutical to discontinue its cell therapy efforts	10-01	RE
Takeda Pharmaceutical Company Limited Provides Update on Cell Therapy Research	10-01	CI
Bristol-Myers Squibb, Takeda Join Apheris' OpenFold3 Drug Discovery AI Model	10-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Takeda CEO Weber on Drug Pipeline, Geopolitical Risks

January 13, 2025 at 03:31 pm